- Home
- ETON vs CIO Comparison
ETON vs CIO Comparison
Compare ETON & CIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- CIO
- Stock Information
- Founded
- ETON 2017
- CIO 2013
- Country
- ETON United States
- CIO Canada
- Employees
- ETON N/A
- CIO N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- CIO Real Estate Investment Trusts
- Sector
- ETON Health Care
- CIO Real Estate
- Exchange
- ETON Nasdaq
- CIO Nasdaq
- Market Cap
- ETON 199.5M
- CIO 230.9M
- IPO Year
- ETON 2018
- CIO 2014
- Fundamental
- Price
- ETON $10.02
- CIO $4.88
- Analyst Decision
- ETON Strong Buy
- CIO
- Analyst Count
- ETON 3
- CIO 0
- Target Price
- ETON $12.00
- CIO N/A
- AVG Volume (30 Days)
- ETON 212.9K
- CIO 199.8K
- Earning Date
- ETON 11-12-2024
- CIO 10-31-2024
- Dividend Yield
- ETON N/A
- CIO 8.18%
- EPS Growth
- ETON N/A
- CIO N/A
- EPS
- ETON N/A
- CIO N/A
- Revenue
- ETON $34,677,000.00
- CIO $173,528,000.00
- Revenue This Year
- ETON $19.61
- CIO N/A
- Revenue Next Year
- ETON $82.71
- CIO $0.25
- P/E Ratio
- ETON N/A
- CIO N/A
- Revenue Growth
- ETON 5.64
- CIO N/A
- 52 Week Low
- ETON $3.03
- CIO $4.02
- 52 Week High
- ETON $11.11
- CIO $6.71
- Technical
- Relative Strength Index (RSI)
- ETON 67.30
- CIO 32.25
- Support Level
- ETON $8.76
- CIO $5.01
- Resistance Level
- ETON $11.11
- CIO $5.43
- Average True Range (ATR)
- ETON 0.66
- CIO 0.21
- MACD
- ETON 0.10
- CIO -0.04
- Stochastic Oscillator
- ETON 62.02
- CIO 7.38
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About CIO City Office REIT Inc.
City Office REIT Inc is a real estate investment trust. It is focused on acquiring, owning, and operating high-quality office properties located predominantly in Sun Belt markets. The principal objective of the company is to provide attractive risk-adjusted returns to its investors over the long-term through a combination of dividends and capital appreciation. The company owns office buildings in the metropolitan areas of Dallas, Denver, Orlando, Phoenix, Portland, Raleigh, San Diego, Seattle, and Tampa.